12 February 2003 13:22
Leading medical device executives join Angiotech management team
VANCOUVER, Feb. 12 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) is pleased to announce today that
George Daniloff, MD, PhD, and Ross Erickson, BA, MA, have joined the company's senior management team. Dr. Daniloff
will add to Angiotech's expertise in biomaterials, acting as General Manager and Vice President of Research and
Development of the California facility. Mr. Erickson will join the Company as Vice President, Operations and oversee
Angiotech's operations as well as Cohesion's clinical, regulatory, quality assurance and quality control. Dr.
Daniloff and Mr. Erickson will also continue on as part of the Integration Team that is coordinating the assimilation
process. Their dedication to the acquisition has been a key to the seamless amalgamation of both companies. Dr. Daniloff
brings to Angiotech over 12 years of experience in the areas of research and development at various pharmaceutical and
biotechnology companies. Prior to accepting this position, he was Vice President, Research and Development at Cohesion.
Mr. Erickson brings to Angiotech over 30 years of experience in the areas of clinical and regulatory affairs at various
pharmaceutical and biotechnology companies. He was instrumental in getting six products through ten approvals in
jurisdictions such as the United States, Europe, Canada, Australia and Japan. Previously, Mr. Erickson was Vice
President, Regulatory Affairs and Clinical Research at Cohesion. "We immediately recognized the value and
experience that both Ross and Eric brought to the table when we began the acquisition discussions with Cohesion,"
said William L. Hunter, MD, MSc, President and Chief Executive Officer at Angiotech. "We felt they would strengthen
our internal capabilities, which was the reason we intentionally kept senior positions open during the
negotiations." Dr. Daniloff received his PhD in biochemistry from the Cardiology Research Center at the Academy of
Medical Sciences in Moscow, and his Doctorate of Medicine from the State Medical University of Russia in Moscow. Dr.
Daniloff has published numerous papers and is named on multiple patents. He conducted postdoctoral research at the
University of North Carolina, Chapel Hill, and also at St. Elizabeth's Medical Center in Boston. Mr. Erickson
received his MA (physiology) and BA (biology) from Western Michigan University and also completed the Stanford Graduate
School of Business Executive Education Program. Previous experiences also include positions at Alza Corporation, Applied
Immune Sciences and Collagen Corporation. Angiotech Pharmaceuticals, Inc. (www.angiotech.com) is dedicated to enhancing
the performance of medical devices and biomaterials through the innovative use of pharmacotherapeutics. Statements in
this press release regarding future financial and operating results of the combination of Angiotech and Cohesion,
benefits and synergies of the combination, future opportunities for the combined company, discovery and development of
products, potential acquisitions, strategic alliances and intellectual property, and any other statements about
Angiotech or Cohesion managements' future expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements
that are not statements of historical fact (including statements containing the words "believes,"
"plans," "anticipates," "expects," estimates and similar expressions) should also be
considered to be forward-looking statements. There are a number of important factors that could cause actual results or
events to differ materially from those indicated by such forward-looking statements, including: the inability of
Angiotech to successfully integrate Cohesion's operations and employees; the inability to realize anticipated
synergies and cost savings; the inability to obtain assignment for licenses with third parties; adverse results in drug
discovery and clinical development processes; failure to obtain patent protection for discoveries; commercialization
limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to
develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from the combined company's development efforts; the
requirement for substantial funding to conduct research and development and to expand commercialization activities; and
any other factors that may affect performance. Given these uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. Angiotech and Cohesion disclaim any obligation to update any such factors
or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect
future results, events or developments. %SEDAR: 00009314E
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=82113 /For further
information: Angiotech Pharmaceuticals Contacts: Rui Avelar, (investors) ext. 6996, Cindy Yu (media) ext. 6901, Phone:
(604) 221-7676/ (ANP. ANPI)
[CAIW [Corporate Announcements Intelligence Wire]] |
RUSSIA IN FACTS
